4basebio Plc - Appointment of Joint Corporate Broker
14 Novembre 2024 - 8:00AM
UK Regulatory
4basebio Plc - Appointment of Joint
Corporate Broker
PR Newswire
LONDON, United Kingdom, November 14
14
November 2024
4basebio
PLC
("4basebio" or the
"Company")
Appointment of
Joint Corporate Broker
14 November 2024 – 4basebio PLC (AIM:
4BB) (“4basebio” or the “Company”), which develops and
commercialises the large scale manufacture of synthetic DNA as well
as nanoparticle delivery solutions, announces the appointment of
RBC Capital Markets as the Company's joint corporate broker, to
work alongside Cavendish Capital Markets, with immediate
effect.
Enquiries
|
4basebio
PLC
Dr. Heikki
Lanckriet
|
+44 (0)1223 967
943
|
|
Joint Corporate
Broker
RBC Capital
Markets
Rupert Walford / Kathryn
Deegan
|
+44 (0)20 7653
4000
|
|
Joint Corporate
Broker
Cavendish Capital
Markets Limited
Geoff Nash / Nigel
Birks
|
+44 (0)20 7220
0500
|
|
|
|
|
Nominated
Adviser
Cairn Financial
Advisers LLP
Jo Turner / Sandy Jamieson
/ Ed Downes
|
+44 (0)20 7213
0880
|
Notes to
Editors
About
4basebio
4basebio (AIM: 4BB) is an
innovation driven life biotechnology company focused on
accelerating the development of advanced therapy medicinal products
(ATMPs) through its high-performance synthetic DNA products and
non-viral, cell targeting nucleic acid delivery platform. The
Company’s objective is to become a market leader in the manufacture
and supply of high-quality synthetic DNA products for research,
therapeutic and pharmacological use as well as development of
target specific non-viral vectors for the efficient delivery of
payloads in patients.
Grafico Azioni 4basebio (LSE:4BB)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni 4basebio (LSE:4BB)
Storico
Da Nov 2023 a Nov 2024
